南模生物受邀参加IGC第三届中国国际免疫&基因治疗论坛
随着NMPA陆续批准前沿的免疫治疗IND注册，越来越多创新疗法从实验室走向临床、从学术走向产业化，然而随之也带来了新的挑战：
双轨制下细胞免疫治疗申报何去何从？
CAR-T疗法何时获批上市走向盈利之路？
如何加深免疫学机制理解开发下一代免疫治疗药物？
如何布局肿瘤免疫联合治疗产品管线？
面对前沿创新疗法的转化与工艺挑战，IGC China 2019 （第三届中国国际免疫&基因治疗论坛）于2019年8月30日-31日在北京新云南皇冠假日酒店顺利召开。会议从药物发现、医学转化、产业化三个角度、两大专场六大专题出发，解析国内外免疫及基因治疗政策与监管趋势，探讨国内外细胞免疫治疗、大小分子免疫治疗及治疗性肿瘤疫苗、溶瘤病毒免疫基因治疗的新研究、新技术、新产品的领先突破，促进国家的产学研医的深入交流与合作，加快免疫及基因治疗的产业转化。
南模生物受邀参加本次会议，现场与各位参会嘉宾进行了交流与探讨。
图 会议现场。
图 展位现场。
你也可能感兴趣
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
查看SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
查看At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
查看
